Japan· JP-1243001X1010
パパベリン塩酸塩
A papaverine product containing パパベリン塩酸塩, registered in Japan, on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Papaverine is registered in 9 of 19 countries.
Countries holding a registration under ATC A03AD01 (papaverine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 5 of them publish a price we can compare per daily dose
Papaverine · ATC A03AD01
9 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Finlandprice
- Japan
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- パパベリン塩酸塩
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- A03AD01
- ATC class
- Papaverine
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
281 interactions on record for papaverine.
Graded by severity as the source publishes them — 216 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Papaverine · interactions on record
281 records
- 216 severe
- 63 moderate
- 2 minor
Most severe, free to view
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A03AD01
Papaverine, as other registers publish it.
- FinlandPapaverinOy Leiras Finland Ab
- FinlandPapaverinOy Leiras Finland Ab
- DenmarkPapaverin "OBA"Oba-Pharma ApS
- United KingdomPapaverine 200mg/10ml solution for injection vialsSpecial Order
- United KingdomPapaverine 20mg/1ml solution for injection ampoulesSpecial Order
- United KingdomPapaverine 300mg/10ml solution for injection vialsSpecial Order
- United KingdomPapaverine 30mg/1ml solution for injection ampoulesSpecial Order
- United KingdomPapaverine 30mg/1ml solution for injection vialsSpecial Order
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c4e30ea9-6b24-4179-bc31-63f97e50770f GET /v1/drugs/c4e30ea9-6b24-4179-bc31-63f97e50770f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１ｇ",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "1243001X1010",
"category": "内用薬",
"price_yen": null,
"generic_name": "パパベリン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1243",
"transitional_expiry": null
}See everything about papaverine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.